Pure Global
NCT04856215

90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia

90Yttrium-labelled Anti-CD66 Monoclonal Antibody as Part of a Reduced Toxicity Conditioning Regimen Prior to Allogeneic Haematopoietic Stem Cell Transplantation: an Open Label, Phase II Study in Children and Adolescents With High Risk Leukaemia
Great Ormond Street Hospital for Children NHS Foundation Trust·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Leukemia
Drug/Device/Intervention
90-Yttrium-labelled anti-CD66 monoclonal antibody
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Great Ormond Street Hospital for Children NHS Foundation Trust
Timeline & enrollment
Phase
Phase 2
Start date
Jan 01, 2022
End date
Jun 01, 2024
Enrollment
25 participants
Primary outcome

Disease response after [90Y]-labelled anti-CD66 monoclonal antibody

Summary

Children affected by high risk or relapsed/refractory leukaemia have a poor prognosis, with
 an increased risk of relapse. These patients generally need treatment intensification and a
 bone marrow transplantation (BMT).
 
 Nevertheless, with conventional treatent the risk of relapse after transplant remains high.
 
 Radioimmunotherapy provides a way to deliver high dose irradiation to the bone marrow (where
 leukaemia resides), while sparing normal organs and tissues from its toxicity.This can be
 achieved by linking a radioactive molecule (Yttrium90) to an antibody that, once infused in
 the blood, targets marrow/leukemic cells.

ICD-10 classifications
Leukaemia, unspecifiedMyeloid leukaemiaMyeloid leukaemia, unspecifiedOther myeloid leukaemiaMonocytic leukaemia, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04856215
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04856215 through Pure Global AI's free database. This Phase 2 trial is sponsored by Great Ormond Street Hospital for Children NHS Foundation Trust and is currently Not yet recruiting. The study focuses on Leukemia. Target enrollment is 25 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.